In cancer cells, PP2A is rarely mutated and is predominantly inactivated by non‐genetic mechanisms.[15] The non‐genetic and selective inhibition of PP2A by inhibitor proteins allows for therapeutic reactivation of the tumor suppressor activity of PP2A.[16, 17]. This evidence concerns the gene PTPA and neoplasm.